[CAS NO. 1809249-37-3] Remdesivir

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1809249-37-3]

Catalog

HY-104077

Brand

MCE

CAS

1809249-37-3

DESCRIPTION [1809249-37-3]

Overview

MDL	MFCD31657351
Molecular Weight	602.58
Molecular Formula	C27H35N6O8P
SMILES	C[C@H](N[P@@](OC1=CC=CC=C1)(OC[C@H]2O[C@@](C#N)(C3=CC=C4C(N)=NC=NN43)[C@H](O)[C@@H]2O)=O)C(OCC(CC)CC)=O

For research use only. We do not sell to patients.

114 Publications Citing Use of MCE

Summary

Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC ₅₀ s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro ^[1] ^[2] ^[3] .

IC50 & Target

EC ₅₀ : 30 nM (murine hepatitis virus, delayed brain tumor cell), 74 nM (SARS-CoV, HAE cell), 74 nM (MERS-CoV, HAE cell) ^[1]
EC ₅₀ : 3.3 μM (SARS-CoV-2), 4.7 μM (SARS-CoV-2 alpha), 32 μM (SARS-CoV-2 beta), 3.7 μM (SARS-CoV-2 gamma) and 9.2 μM (SARS-CoV-2 delta) ^[3]

In Vitro

Remdesivir (GS-5734) inhibits murine hepatitis virus (MHV) with an EC ₅₀ of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC ₅₀ s of both 74 nM in HAE cells after treatment for 24 h ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04745351	Gilead Sciences	COVID-19	March 31, 2021	Phase 3
NCT04492501	UNICEF\|Pak Emirates Military Hospital Rawalpindi	Covid19\|Cytokine Release Syndrome\|Critical Illness\|ARDS	April 1, 2020	Not Applicable
NCT05222113	Bernadette Dian Novita, MD.,PhD\|Universitas Katolik Widya Mandala Surabaya	Duration of Hospitalization\|Clinical Manifestation of COVID-19	August 1, 2021
NCT04539262	Gilead Sciences	COVID-19	September 14, 2020	Phase 1\|Phase 2
NCT04480333	NeuroActiva, Inc.	Covid19\|Corona Virus Infection\|Severe Acute Respiratory Syndrome\|Severe Acute Respiratory Infection\|Severe Acute Respiratory Syndrome (SARS) Pneumonia\|Severe Acute Respiratory Syndrome of Upper Respiratory Tract\|Neurodegeneration\|Neuroinflammatory Response	September 15, 2020	Phase 1
NCT04865237	Imperial College London\|Hvivo\|Royal Free Hospital NHS Foundation Trust	Covid19\|SARS-CoV Infection\|Corona Virus Infection\|Coronavirus\|COVID-19	March 6, 2021	Not Applicable
NCT04647695	The University of Hong Kong	Covid19	November 20, 2020	Phase 2
NCT04349410	The Camelot Foundation	CoVid 19 Positive	April 11, 2020	Phase 2\|Phase 3
NCT04391309	National Institute of Allergy and Infectious Diseases (NIAID)\|University of Washington\|Implicit Bioscience\|Vanderbilt University Medical Center\|PPD	Coronavirus Disease 2019 (COVID-19)\|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	April 12, 2021	Phase 2
NCT04292730	Gilead Sciences	COVID-19	March 15, 2020	Phase 3
NCT04596839	Dr. Md. Alimur Reza\|Beximco Pharmaceuticals Ltd.	Covid19	September 4, 2020	Phase 2
NCT04492475	National Institute of Allergy and Infectious Diseases (NIAID)	COVID-19	August 5, 2020	Phase 3
NCT03719586	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Ebola Virus	November 21, 2018	Phase 2\|Phase 3
NCT04854837	Semmelweis University	Covid19\|End Stage Renal Failure on Dialysis	April 12, 2021
NCT05041907	University of Oxford	COVID-19	September 30, 2021	Phase 2
NCT04832880	ASST Fatebenefratelli Sacco	Covid19	April 6, 2021	Phase 3
NCT03511118	Duke University\|The Emmes Company, LLC\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Lactating Women on Select DOI\|Breastfed Infants of Mothers on Select DOI	October 4, 2018
NCT05502081	Mansoura University Hospital	COVID-19	November 1, 2021	Phase 4
NCT04280705	National Institute of Allergy and Infectious Diseases (NIAID)	COVID-19	February 21, 2020	Phase 3
NCT04693026	M Abdur Rahim Medical College and Hospital\|First affiliated Hospital Xi´an Jiaoting University	Covid19\|Covid-19 ARDS	September 10, 2020	Phase 3
NCT04583956	National Institute of Allergy and Infectious Diseases (NIAID)	COVID-19	October 14, 2020	Phase 2
NCT04488081	QuantumLeap Healthcare Collaborative\|University of California, San Francisco\|University of Pennsylvania\|Emory University\|University of Alabama at Birmingham\|University of Colorado, Denver\|University of Southern California\|Yale University\|Columbia University\|Wake Forest University Health Sciences\|Sanford Health\|Long Beach Memorial Medical Center\|Georgetown University\|University of California, Davis\|Hoag Memorial Hospital Presbyterian\|University of Iowa\|Main Line Health\|Northwestern University\|DHR Health Institute for Research and Development\|Mercy Hospital Springfield\|University of California, Irvine\|Spectrum Health Hospitals\|Kaiser Permanente\|University of Rochester\|University of Michigan\|West Virginia University\|Stamford Hospital\|University of Miami\|University Hospitals Cleveland Medical Center\|Logan Health\|Virtua Memorial Hospital Mount Holly\|Sanford USD Medical Center\|UC Irvine Medical Center\|University of Florida Health Shands Hospital\|M.D. Anderson Cancer Center	COVID-19	July 31, 2020	Phase 2
NCT04640168	National Institute of Allergy and Infectious Diseases (NIAID)	COVID-19	December 2, 2020	Phase 3
NCT04727775	Astana Medical University	Complication of Medical Care\|Pneumonia, Viral	December 1, 2020
NCT04784559	PharmaMar	COVID-19 Infection	June 4, 2021	Phase 3
NCT04323761	Gilead Sciences	SARS-CoV2 Infection
NCT04871633	King Edward Medical University	COVID-19	August 1, 2020	Not Applicable
NCT04321993	Lisa Barrett\|Nova Scotia Health Authority\|Dalhousie University	COVID-19	April 17, 2020	Phase 2
NCT04431453	Gilead Sciences	COVID-19	July 21, 2020	Phase 2\|Phase 3
NCT04779047	October 6 University\|Beni-Suef University	Covid19\|Pneumonia	October 1, 2020	Phase 4
NCT02818582	National Institute of Allergy and Infectious Diseases (NIAID)\|Gilead Sciences\|National Institutes of Health Clinical Center (CC)	Ebola	July 1, 2016	Phase 2
NCT04647669	The University of The West Indies	Covid19	June 1, 2021	Phase 3
NCT04252664	Capital Medical University\|Cancer Institute and Hospital, Chinese Academy of Medical Sciences	COVID-19\|SARS-CoV-2	February 12, 2020	Phase 3
NCT04853901	Ain Shams University	Covid19	July 27, 2020	Phase 3
NCT04583969	National Institute of Allergy and Infectious Diseases (NIAID)	COVID-19	October 19, 2020	Phase 2
NCT04678739	M Abdur Rahim Medical College and Hospital\|First Affiliated Hospital Xi´an Jiaotong University\|Cox´s Bazar 250 Bed District Sadar Hospital\|Chattogram General Hospital	Covid19\|Covid-19 ARDS	August 15, 2020	Phase 3
NCT04292899	Gilead Sciences	COVID-19	March 6, 2020	Phase 3
NCT04713176	Daewoong Pharmaceutical Co. LTD.	Severe COVID-19	February 2, 2021	Phase 3
NCT04302766	U.S. Army Medical Research and Development Command	Coronavirus Disease 2019
NCT04738045	Ahmed Essam\|Beni-Suef University\|October 6 University	Covid19	November 1, 2020	Phase 4
NCT04385719	Makerere University\|University of Liverpool\|European and Developing Countries Clinical Trials Partnership (EDCTP)\|University of Turin, Italy	Ebola\|HIV+AIDS	May 5, 2021	Phase 2
NCT04501978	University of Minnesota\|International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)\|University of Copenhagen\|Medical Research Council\|Kirby Institute\|Washington D.C. Veterans Affairs Medical Center\|AIDS Clinical Trials Group\|National Heart, Lung, and Blood Institute (NHLBI)\|US Department of Veterans Affairs\|Prevention and Early Treatment of Acute Lung Injury (PETAL)\|Cardiothoracic Surgical Trials Network (CTSN)\|Eli Lilly and Company\|Vir Biotechnology, Inc.\|GlaxoSmithKline\|Brii Biosciences Limited\|AstraZeneca\|Molecular Partners AG\|National Institute of Allergy and Infectious Diseases (NIAID)\|Pfizer	Covid19	August 4, 2020	Phase 3
NCT04694612	Nepal Health Research Council	Covid19	January 1, 2021	Phase 3
NCT04582266	National Institute of Allergy and Infectious Diseases (NIAID)	COVID-19	February 12, 2021
NCT04345419	Tanta University	COVID	June 16, 2020	Phase 2\|Phase 3
NCT04257656	Capital Medical University	COVID-19\|Remdesivir\|SARS-CoV-2	February 6, 2020	Phase 3
NCT04988035	National Institute of Allergy and Infectious Diseases (NIAID)	COVID-19	July 21, 2021	Phase 2
NCT04321616	Oslo University Hospital	SARS-CoV Infection\|COVID 19\|Acute Respiratory Distress Syndrome ARDS	March 28, 2020	Phase 2\|Phase 3
NCT04546581	University of Minnesota\|National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health (NIH)\|International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)	COVID\|COVID-19\|SARS-CoV-2\|SARS (Severe Acute Respiratory Syndrome)	October 8, 2020	Phase 3
NCT04728880	Mansoura University	Pneumonia, Viral	January 26, 2021
NCT04847622	NEAT ID Foundation\|Gilead Sciences	Covid19	February 1, 2021
NCT05024006	University of the Philippines	Covid19	April 23, 2020	Not Applicable
NCT04970719	Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders	COVID-19 Pneumonia	July 10, 2021	Phase 3
NCT04560231	Lahore General Hospital	SARS-CoV Infection	June 1, 2020	Early Phase 1
NCT04365725	Assistance Publique - Hôpitaux de Paris	COVID-19	May 5, 2020
NCT04978259	Clinical Urology and Epidemiology Working Group\|University of Helsinki\|World Health Organization\|Helsinki University Central Hospital\|Hyvinkää Hospital\|Kanta-Häme Central Hospital\|Kuopio University Hospital\|Oulu University Hospital\|Porvoo Hospital\|Seinajoki Central Hospital\|Mikkeli Central Hospital\|Tampere University Hospital	Covid19	July 24, 2021	Phase 4
NCT04410354	ViralClear Pharmaceuticals, Inc.	COVID-19	June 16, 2020	Phase 2
NCT04593940	Daniel Benjamin\|National Center for Advancing Translational Sciences (NCATS)\|Biomedical Advanced Research and Development Authority\|Duke University	Covid19	October 15, 2020	Phase 3
NCT04669990	Nepal Health Research Council	Covid19	November 19, 2020
NCT04409262	Hoffmann-La Roche\|Gilead Sciences	COVID-19 Pneumonia	June 16, 2020	Phase 3
NCT04315948	Institut National de la Santé Et de la Recherche Médicale, France	Corona Virus Infection	March 22, 2020	Phase 3
NCT04351724	Medical University of Vienna\|Kaiser Franz Josef Hospital\|SMZ-Ost Donauspital\|Otto Wagner Hospital\|Hospital Hietzing\|Wilhelminenspital Vienna\|Medical University Innsbruck\|Medical University of Graz\|Kepler University Hospital	COVID-19	April 16, 2020	Phase 2\|Phase 3
NCT04575064	Professor Dr. Bernd Mühlbauer\|Dept. of Statistics and Medical Biometry, University of Bremen\|INSERM (Institut national de la santé et de la recherche médicale), Paris, France\|World Health Organization (WHO), R&D Blueprint, Geneva, Switzerland\|Klinikum Bremen-Mitte, gGmbH	SARS-CoV-2 Infection\|COVID-19\|Moderate and Severe COVID-19	June 29, 2020	Phase 2\|Phase 3
NCT04401579	National Institute of Allergy and Infectious Diseases (NIAID)	COVID-19	May 8, 2020	Phase 3
NCT05185284	Promomed, LLC\|Solyur Pharmaceuticals Group	COVID-19	August 11, 2021	Phase 3
NCT04843761	National Institute of Allergy and Infectious Diseases (NIAID)\|International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)\|University of Copenhagen\|Medical Research Council\|Kirby Institute\|Washington D.C. Veterans Affairs Medical Center\|AIDS Clinical Trials Group\|National Heart, Lung, and Blood Institute (NHLBI)\|US Department of Veterans Affairs\|Prevention and Early Treatment of Acute Lung Injury (PETAL)\|Cardiothoracic Surgical Trials Network (CTSN)\|NeuroRx, Inc.\|Gilead Sciences	Covid19	April 20, 2021	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 165.95 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6595 mL	8.2977 mL	16.5953 mL
5 mM	0.3319 mL	1.6595 mL	3.3191 mL
10 mM	0.1660 mL	0.8298 mL	1.6595 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.15 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.17 mg/mL (3.60 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.17 mg/mL (3.60 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

L-Alanine, N-[(S)-hydroxyphenoxyphosphinyl]-, 2-ethylbutyl ester, 6-ester with 2-C-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-D-altrononitrile

GS 5734

Remdesivir

2-Ethylbutyl N-[(S)-[2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-D-altrononitril-6-O-yl]phenoxyphosphoryl]-L-alaninate

2-Ethylbutyl (2S)-2-[[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy]phenoxyphosphoryl]amino]propanoate

L-Alanine, N-[(S)-hydroxyphenoxyphosphinyl)-, 2-ethylbutyl ester,6-ester with 2-C-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-D-altrononitrile

2-Ethylbutyl (2S)-2-[[(S)-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy]phenoxyphosphoryl]amino]propanoate

GS-5734

Veklury